Rivaroxaban
- PDF / 169,401 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 71 Downloads / 154 Views
1
Rivaroxaban Bleeding: case report In a single-centre, retrospective study of 281 patients, who had cancer of the GI tract and underwent treatment for venous thromboembolism (VTE) at a hospital in Korea between 1 January 2012 and 31 December 2016, one patient was described [age and sex not stated], who experienced fatal bleeding secondary to rivaroxaban. The patient started receiving oral rivaroxaban 15mg twice daily with food for 21 days, followed by 20mg once daily for VTE. However, the patient subsequently developed bleeding secondary to rivaroxaban [time to reaction onset not stated]. The patient died due to the bleeding. Author comment: "[R]ivaroxaban may increase the risk of bleeding in VTE patients with GI tract cancer." "After 6 months from anticoagulants start day, 167 patients had died. Of these, 29 (37.2%) deaths occurred in the rivaroxaban group. These included 1 death secondary to bleeding." Lee JH, et al. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer. Journal of Korean Medical Science 34: No. 21, 2019. Available from: URL: http:// 803441364 doi.org/10.3346/jkms.2019.34.e160 - South Korea
0114-9954/19/1784-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Dec 2019 No. 1784
Data Loading...
